Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Fineline Cube May 7, 2026
Company Deals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

Fineline Cube May 7, 2026
Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Hospital Policy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Fineline Cube May 7, 2026
Company Drug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Fineline Cube May 7, 2026
Company Drug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

Fineline Cube May 7, 2026
Company

Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919

Fineline Cube Aug 10, 2023

US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...

Company Deals

Poseida Therapeutics Secures $50 Million Investment from Astellas for Cell and Gene Therapy

Fineline Cube Aug 10, 2023

US-based cell and gene therapy developer Poseida Therapeutics, Inc. (NASDAQ: PSTX) has announced a significant...

Company Drug

Lee’s Pharmaceutical’s Subsidiary Completes Phase III Study for Myopia Treatment NVK002

Fineline Cube Aug 10, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Company Medical Device

Eyebright Medical Technology’s Intraocular Lenses Earn Fast-Track Status in China

Fineline Cube Aug 10, 2023

Beijing-based Eyebright Medical Technology Co., Ltd (SHE: 688050) has announced that its “intraocular lenses with...

Company Deals

Neurophth Biotechnology Secures RMB700 Million in Series C+ Financing for Gene Therapy Development

Fineline Cube Aug 10, 2023

China-based gene therapy specialist Neurophth Biotechnology Ltd has reportedly secured close to RMB700 million in...

Company Drug

Novartis Reports Positive Phase III Results for Remibrutinib in Chronic Spontaneous Urticaria

Fineline Cube Aug 10, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) has announced positive data from the Phase III...

Company Deals

Burning Rock Partners with AstraZeneca to Develop Companion Diagnostics for Cancer Therapies

Fineline Cube Aug 9, 2023

Guangzhou-based medical device giant Burning Rock (NASDAQ: BNR) has announced a strategic partnership with AstraZeneca...

Company Policy / Regulatory

Audit Reveals Illicit Payments and Inflated Prices in Pharmaceutical Industry

Fineline Cube Aug 9, 2023

An audit has shed light on the use of third-party business promotion companies as a...

Company

Eli Lilly & Co. Reports 28% YOY Revenue Increase in Q2 2023 Financials

Fineline Cube Aug 9, 2023

US pharmaceutical giant Eli Lilly & Co., (NYSE: LLY) has released its financial results for...

Company

FibroGen’s Evrenzo Achieves Record Sales in China, Outlook for 2024 Remains Promising

Fineline Cube Aug 9, 2023

US-based biopharmaceutical company FibroGen Inc., (NASDAQ: FGEN) has released its financial report for the second...

Company

Bayer AG Reports Q2/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals

Fineline Cube Aug 9, 2023

Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter...

Company Drug

Novo Nordisk’s Wegovy Demonstrates 20% Reduction in Cardiovascular Events in SELECT Trial

Fineline Cube Aug 9, 2023

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has released topline data supporting the use...

Policy / Regulatory

Shanghai Health Commission Issues Regulations to Curb Unhealthy Pharmaceutical Practices

Fineline Cube Aug 9, 2023

In alignment with the No. 75 Document by the National Health Commission, the Shanghai...

Company Deals

CanSino Biotechnology Partners with AstraZeneca for mRNA Vaccine Development and Manufacturing

Fineline Cube Aug 9, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced a product supply cooperation framework...

Company Drug

Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Atopic Dermatitis Phase II Study

Fineline Cube Aug 9, 2023

China-based Lynk Pharmaceuticals Co., Ltd has announced that its Phase II clinical study for LNK01001...

Company Deals

BioNTech Expands Partnership with Duality Biologics for Global Rights to ADC DB-1305

Fineline Cube Aug 8, 2023

Germany-based BioNTech SE (NASDAQ: BNTC) has entered into a cooperation expansion agreement with its existing...

Company Legal / IP

Johnson & Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar

Fineline Cube Aug 8, 2023

US pharmaceutical giant Johnson & Johnson (J&J; NYSE: JNJ) has entered into its latest settlement...

Company Drug

VistaGen’s Fasedienol Phase III Success Sends Shares Soaring Over 600%

Fineline Cube Aug 8, 2023

Shares of San Francisco-based biotech VistaGen (NASDAQ: VTGN) experienced a dramatic increase of over 600%...

Company Legal / IP

Nektar Therapeutics and Eli Lilly & Co. Face Off in Court Over REZPEG Partnership Dispute

Fineline Cube Aug 8, 2023

A legal feud between US-based Nektar Therapeutics (NASDAQ: NKTR) and pharmaceutical giant Eli Lilly &...

Company Drug

BioCity Biopharma Receives FDA IND Approval for CD3-EGFR BsAb BC3448

Fineline Cube Aug 8, 2023

China-based biotechnology company BioCity Biopharma has announced that it has received Investigational New Drug (IND)...

Posts pagination

1 … 486 487 488 … 661

Recent updates

  • Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist
  • GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook
  • Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%
  • Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion
  • China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bayer to Acquire Perfuse Therapeutics for Up to $2.45 Billion – Expands Ophthalmology Portfolio with Phase 2 Endothelin Receptor Antagonist

Company

GSK Reports Solid Q1 2026 Results – Specialty Medicines and Shingrix Drive Growth as Company Maintains Strong 2031 Outlook

Company

Novo Nordisk Reports Record Q1 2026 Results – Wegovy Pill Achieves Strongest-Ever GLP-1 Launch as Total Sales Surge 32%

Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.